SCHEMBL3279154

SCHEMBL3279154

O=C(c1cncnc1)C1CCc2nc(NC(O)=S)sc2C1=O

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.38
NPC1 O15118 7/20 0.38
RAB9A P51151 7/20 0.38
SMN1; SMN2 Q16637 6/20 0.38
POLB P06746 2/20 0.38
TP53 P04637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 1/20 0.32
THRB P10828 1/20 0.32
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.30
GSK3B P49841 1/20 0.30
CSNK2A1 P68400 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3279143 0.88 ALDH1A1 (0.37) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL3273615 0.88 LMNA (0.39) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL10103045 0.82 ALDH1A1 (0.34) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL3273645 0.78 ALDH1A1 (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL3310236 0.76 ALDH1A1 (0.31) ALDH1A1
SCHEMBL3277195 0.75 ALDH1A1 (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL798617 0.75 PIK3CG (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL2144189 0.75 ALDH1A1 (0.50) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL10103040 0.74 ALDH1A1 (0.45) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL1117899 0.71 PIK3CG (0.41) ALDH1A1NPC1RAB9ASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691888-B2 Thiazolyl-dihydro-indazole BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-06 US disclosed
US-20060100254-A1 N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100254-A1 N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases CDK1, MAPK1, NFATC1 ALDH1A1 1013/4885NPC1 920/4885RAB9A 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.